HTX-034 + HTX-034 + Bupivacaine HCl
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bunions
Conditions
Bunions
Trial Timeline
May 18, 2020 → Aug 3, 2021
NCT ID
NCT04398329About HTX-034 + HTX-034 + Bupivacaine HCl
HTX-034 + HTX-034 + Bupivacaine HCl is a phase 1/2 stage product being developed by Heron Therapeutics for Bunions. The current trial status is completed. This product is registered under clinical trial identifier NCT04398329. Target conditions include Bunions.
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04398329 | Phase 1/2 | Completed |